1.TACE combined with CBCT-guided MWA simultaneous treatment for small hepatocellular carcinoma:analysis of clinical efficacy and safety
Bin YU ; Yu YIN ; Jun YANG ; Pengchen TIAN ; Lin XU ; Jia'an DING ; Xiaoyun MIAO ; Caifang NI
Journal of Interventional Radiology 2025;34(12):1321-1327
Objective To investigate the clinical efficacy and safety of simultaneous treatment of small hepatocellular carcinoma(HCC)with transarterial chemoembolization(TACE)combined with cone-beam computed tomography-guided(CBCT-guided)microwave ablation(MWA).Methods The clinical data of 69 patients with small HCC(72 lesions in total),who underwent TACE combined with CBCT-guided MWA simultaneous treatment from March 2018 to December 2022 at First Affiliated Hospital of Soochow University hospital,were retrospectively analyzed.Follow-up check was performed at 1,3,6,and 12 months after treatment.The mRECIST criteria was used to evaluate the tumor response.The objective response rate(ORR),disease control rate(DCR),progression-free survival(PFS),local tumor progression(LTP),and adverse reactions were analyzed.Results The initial complete remission(CR)rate,ORR and DCR of TACE combined with CBCT-guided MWA simultaneous treatment for small HCC was 94.2%(65/69),100%and 100%respectively.44.9%(31/69)of patients experienced tumor progression,and 20.3%(14/69)of patients experienced local tumor progression.Univariate and multivariate analyses showed that the maximum tumor diameter(≥2 cm and<3 cm)was the main risk factor for PFS(HR=4.498,P<0.001).No serious adverse events occurred during the study.Conclusion TACE combined with CBCT-guided MWA simultaneous treatment for small HCC is clinically effect and safe,and this therapy is particularly suitable for the treatment of lesions where the use of traditional image-guided methods is limited.

Result Analysis
Print
Save
E-mail